
Spanish drugmaker Almirall (ALM: MC) was trading 4% higher by lunchtime on Friday following news that it is to acquire the US medical dermatology portfolio of Ireland-incorporated Allergan (NYSE: AGN).
The deal earns Allergan a $550 million cash consideration plus up to $100 million more in milestone payments, while the five products that the Barcelona-based company is picking up include mature and growth brands for acne and dermatoses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze